Literature DB >> 31806742

Draft Genome Sequence of a Metronidazole-Resistant Bacteroides fragilis Strain Isolated in Ecuador.

Jeannete Zurita1,2, Gabriela Sevillano2, Ariane Paz Y Miño2, Francisco Flores3,4, Marcela Bovera5.   

Abstract

Here, we report the draft genome sequence of Bacteroides fragilis strain Z&Z143, a metronidazole-resistant bacterium isolated from a blood culture from an Ecuadorian patient hospitalized in a medical institution in Quito, Ecuador. We describe a new variant of the nim genes, which is associated with metronidazole resistance.
Copyright © 2019 Zurita et al.

Entities:  

Year:  2019        PMID: 31806742      PMCID: PMC6895302          DOI: 10.1128/MRA.01125-19

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

Bacteroides fragilis is a predominant organism in the colon microbiota (1). It is one of the most frequently isolated species from clinical infections and bacteremia (2). The most common antimicrobial drug for the treatment of B. fragilis infections is metronidazole (3). Worldwide, the prevalence of metronidazole-resistant B. fragilis has been reported to be between 0.5% and 7.8% (4). The resistance is often conferred by the nim genes, which encode 5-nitroimidazole reductase (5). Before this analysis, 11 variants of the nim gene (nimA to nimK) had been identified, mainly in Bacteroides spp. and rarely in other anaerobes (6). B. fragilis was isolated from a blood culture from a patient who had abdominal surgery and was hospitalized in Quito, Ecuador. It was obtained using a Bactec lytic anaerobic blood culture bottle (Becton, Dickinson, USA) after routine subculture on a BBL Bacteroides bile esculin (BBE) agar plate (Becton, Dickinson) at 37°C in an anaerobic atmosphere for 24 h. The API 20A system (bioMérieux, Marcy l’Étoile, France) was applied for the identification of B. fragilis (Z&Z143). MICs were determined using a Sensititre anaerobe MIC ANO2B plate (Thermo Fisher Scientific, USA). The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines (7). Total DNA from the B. fragilis Z&Z143 strain, harvested from BBE agar, was extracted using the High Pure PCR template preparation kit (Roche Diagnostics, Switzerland), according to the manufacturer’s instructions. The TruSeq Nano DNA library preparation kit (Illumina) was used to prepare libraries that were sequenced using the Illumina HiSeq system in 100-bp paired-end runs, producing a total of 10,317,898 reads. The Trimmomatic version 0.39 tool was used to trim and filter low-quality reads. Assembly was conducted with Velvet 1.2 (https://cge.cbs.dtu.dk/services/Assembler/) (8), resulting in 75 contigs >200 bp in size and an estimated genome size of 5 Mb. Antimicrobial resistance genes were determined using ResFinder (9). Default parameters were used for all software. The isolated B. fragilis strain was characterized according to its phenotypic and genotyping resistance (Table 1).
TABLE 1

Phenotypic and genotypic antimicrobial susceptibility profile

AntimicrobialMIC breakpoint (mg/liter)Resistance interpretive categoryaResistance gene
Ampicillin-sulbactam16/8RcepA
Amoxicillin-clavulanic acid4/2S
Cefotetan Na≤4S
Penicillin≥4R
Imipenem≤0.12S
Meropenem≤0.5S
Clindamycin≥8RermF
Cefoxitin4S
Metronidazole≥16RnimL
Chloramphenicol≥64RChloramphenicol-acetyltransferase
Ampicillin≥16R
Piperacillin128R
Tetracycline≥8RtetQ
Mezlocillin128NA
Piperacillin-tazobactam2/4S

The results were interpreted using CLSI M100, 29th ed. (7). R, resistant; S, susceptible; NA, CLSI breakpoints were not available.

Phenotypic and genotypic antimicrobial susceptibility profile The results were interpreted using CLSI M100, 29th ed. (7). R, resistant; S, susceptible; NA, CLSI breakpoints were not available. The draft genome of metronidazole-resistant B. fragilis Z&Z143 has a length of 5,158,698 bp, with an N50 value of 196,742 bp, genome coverage of 200.0×, and G+C content of 43.1%. A total of 4,320 protein-coding genes and 71 RNA-coding sequences were detected after manual inspection of the annotations using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/) (10). Functional annotation with the PGAP highlighted genes that were associated with the nitroimidazole reductase protein, which is responsible for the metronidazole resistance in this strain. A BLAST search of the Z&Z143 nitroimidazole resistance gene resulted in a nucleic acid identity of 89% with the nimC gene of Bacteroides thetaiotaomicron (GenBank accession number NG_048013) and 83% with the nimF gene of Bacteroides vulgatus (GenBank accession number AJ515145). The presence of this nim gene in B. fragilis was further confirmed by PCR using the NIM-3 and NIM-5 primers (11). The new variant of the nim gene conferring metronidazole resistance described in this study was named nimL (GenBank accession number MK251988). The increasing diversity of nim gene variants is of great concern because there is a possibility for new emerging multidrug-resistant Bacteroides strains. Furthermore, the activity of metronidazole, traditionally used as an empirical therapy for anaerobic infections, might be compromised.

Data availability.

The genome sequence was deposited under GenBank accession number SRKB00000000, BioProject number PRJNA530267, SRA accession number SRR10193381, and BioSample accession number SAMN11310039.
  10 in total

1.  Multilocus sequence typing of total-genome-sequenced bacteria.

Authors:  Mette V Larsen; Salvatore Cosentino; Simon Rasmussen; Carsten Friis; Henrik Hasman; Rasmus Lykke Marvig; Lars Jelsbak; Thomas Sicheritz-Pontén; David W Ussery; Frank M Aarestrup; Ole Lund
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole.

Authors:  Kenneth E Aldridge; Charles V Sanders
Journal:  Anaerobe       Date:  2002-12       Impact factor: 3.331

Review 3.  Metronidazole resistance and nim genes in anaerobes: A review.

Authors:  Corentine Alauzet; Alain Lozniewski; Hélène Marchandin
Journal:  Anaerobe       Date:  2018-10-11       Impact factor: 3.331

4.  Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis.

Authors:  J P Carlier; N Sellier; M N Rager; G Reysset
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp.

Authors:  S Trinh; G Reysset
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

Review 6.  Metronidazole is still the drug of choice for treatment of anaerobic infections.

Authors:  Sonja Löfmark; Charlotta Edlund; Carl Erik Nord
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

Review 7.  Mechanisms of Bacteroides fragilis resistance to metronidazole.

Authors:  Reza Ghotaslou; Hossein Bannazadeh Baghi; Naser Alizadeh; Mina Yekani; Shahram Arbabi; Mohammad Yousef Memar
Journal:  Infect Genet Evol       Date:  2018-06-21       Impact factor: 3.342

Review 8.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

9.  Identification of acquired antimicrobial resistance genes.

Authors:  Ea Zankari; Henrik Hasman; Salvatore Cosentino; Martin Vestergaard; Simon Rasmussen; Ole Lund; Frank M Aarestrup; Mette Voldby Larsen
Journal:  J Antimicrob Chemother       Date:  2012-07-10       Impact factor: 5.790

10.  NCBI prokaryotic genome annotation pipeline.

Authors:  Tatiana Tatusova; Michael DiCuccio; Azat Badretdin; Vyacheslav Chetvernin; Eric P Nawrocki; Leonid Zaslavsky; Alexandre Lomsadze; Kim D Pruitt; Mark Borodovsky; James Ostell
Journal:  Nucleic Acids Res       Date:  2016-06-24       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.